Established in mid-2018, Spotlight Therapeutics is a privately held biotechnology company advancing a pipeline of cell-targeted in vivo CRISPR gene editing therapies. Spotlight's proprietary technology platform TAGE (Targeted Active Gene Editors) is a new class of biologics, CRISPR effectors engineered for direct delivery in vivo, to achieve cell-selective therapeutic genome editing. Spotlight's pipeline is advancing its modular programmable CRISPR effectors towards clinical studies in immuno-oncology, ophthalmic diseases and hemoglobinopathies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/22/22 | $36,500,000 | Series B |
Emerson Collective EPIQ Capital Group  GordonMD Global Investments GV Magnetic Ventures | undisclosed |
